Takeda Pharmaceuticals USA Inc. - GATTEX
Learn more about GATTEX (teduglutide)
Thank you for visiting our GATTEX booth!
Please click here or go to gattexvirtualbooth.com to visit our GATTEX Virtual Booth experience. Here you can view and download resources including brochures about short bowel syndrome (SBS) and GATTEX.
Indication
GATTEX® (teduglutide) for injection is indicated for the treatment of adults and pediatric patients 1 year of age and older with Short Bowel Syndrome (SBS) who are dependent on parenteral support.
Important Safety Information
Warnings and Precautions
GATTEX has been associated with acceleration of neoplastic growth, intestinal obstruction, biliary and pancreatic disease, fluid imbalance and fluid overload, and increased absorption of concomitant oral medication. .
GATTEX and the GATTEX logo are registered trademarks of Shire-NPS Pharmaceuticals, Inc., a Takeda company. TAKEDA and the TAKEDA logo are registered trademarks of Takeda Pharmaceutical Company Limited. Ⓒ2022 Takeda Pharmaceuticals U.S.A. Inc. All rights reserved.
US-TED-1032v1.0 04/22
Brands: GATTEX (teduglutide)